- Home
- WBS vs KRYS Comparison
WBS vs KRYS Comparison
Compare WBS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WBS | KRYS |
|---|---|---|
| Founded | 1935 | 2015 |
| Country | United States | United States |
| Employees | 4601 | 295 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 9.6B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | WBS | KRYS |
|---|---|---|
| Price | $79.05 | $326.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $73.64 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 4.0M | 610.8K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 3.62 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $5.32 | $38.74 |
| Revenue Next Year | $5.89 | $32.53 |
| P/E Ratio | ★ $12.28 | $89.14 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $52.69 | $137.38 |
| 52 Week High | $79.79 | $382.54 |
Technical Indicators
Market Signals| Indicator | WBS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 42.36 |
| Support Level | $75.23 | $318.87 |
| Resistance Level | N/A | $377.89 |
| Average True Range (ATR) | 0.71 | 17.00 |
| MACD | 0.24 | -4.08 |
| Stochastic Oscillator | 100.00 | 35.66 |
Price Performance
Historical ComparisonAbout WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.